Cyclerion secures $1.75M from praliciguat license amendment, signs olinciguat option deal

Cyclerion Therapeutics, Inc.

Akebia to pay Cyclerion $1.25M by Dec 31, 2024, and $500k by Sep 30, 2025; assumes IP costs after Q1 2025.
Tiered royalties increased to mid-single-digit to 20% on net sales; some development milestones reduced.
Exclusive license option for olinciguat granted to entity controlled by CVCO Therapeutics; grantee pays IP costs.
Proceeds will fund CNS pipeline build; company plans to raise capital as needed to support product plans.
Olinciguat option, if exercised, would complete monetization of Cyclerion's historical sGC stimulator portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.